Valuation
- Market cap
- 125,454,000
- Revenue TTM
- $0
- Net income TTM
- $-26,970,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 18,000
- Avg volume
- 67,352
- Day's range
- $30.57 – $32.32
- Shares out
- 3,939,000
- Stochastic %K
- 33%
- Beta
- 0.21
- Analysts
- Strong Sell
- Price target
- $56.25
Company profile
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a...
Show more
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 336 841 0300
- Website
- https://vtvtherapeutics.com
- Address
- 3980 Premier Drive, Suite 310, High Point, United States
Latest news
No headlines yet.
